Floris Wolswijk’s Post

In September 2023, over 100 new psychedelic research articles were published. I combed through them and put the 25 most exciting studies in this recap 👇 The second Phase III study from MAPS was published, showing that more than 2/3rd of those treated with MDMA-assisted psychotherapy no longer met DSM-5 criteria for PTSD. With 104 participants, the study complements the first Phase III study and marks the transition to the next step in psychedelic research, the FDA approval process. Next to MAPS' landmark study, we were also treated to the largest prospective survey of people using psychedelics outside the clinical setting. In settings outside the lab, respondents generally found benefits such as reduced alcohol misuse, better emotional regulation, and improved spiritual well-being. The data could serve as a counterpoint towards recent negative news around self-experimentation with psychedelics. September was another productive month for psychedelic research, with 25 articles (and full summaries for paying members) added to the database (nearing 2000 articles). In this recap, we also cover exciting news about psychedelics and our immune system, the surprising similarity between MDMA and methamphetamine, and how to prevent history from repeating itself. Continue reading on Blossom 👇 #psychedelicresearch #psychedelics #MDMA